Substance for preventing and improving arthritis

Patent metadata

Field	Value
Publication number	US-9504720-B2
Application number	US-201213983488-A
Country	US
Kind code	B2
Filing date	Jan 18, 2012
Priority date	Feb 2, 2011
Publication date	Nov 29, 2016
Grant date	Nov 29, 2016

Abstract

This application provides a substance containing disrupted cells of an anti-inflammatory lactic acid bacterium and having an effect of preventing or improving arthritis in a subject, a composition containing the substance and the preparation method thereof, and a method for enhancing the effect of preventing and improving arthritis with the use of the substance.

First claim

The invention claimed is:

1. A method for improving one or more symptoms of arthritis in a subject in need thereof comprising:
(a) disrupting cells of a lactic acid bacterium to produce a composition comprising disrupted cells of the lactic acid bacterium;
(b) administering an effective amount of the composition to the subject, wherein the average long diameter and/or surface area of each disrupted cell is 90% or less of that of the lactic acid bacterial cells before disruption.

2. The method of claim 1 , wherein the disrupting step is conducted via physical disruption, chemical treatment, or enzymatic lysis.

3. The method of claim 1 , wherein the lactic acid bacterium is Lactobacillus acidophilus CL-92 strain (FERM BP-4981), Lactobacillus amylovorus CP1563 strain (FERM BP-11255) or Lactobacillus gasseri CP2305 strain (FERM BP-11331), or a mutant strain thereof or derived strain therefrom.

4. The method of claim 1 , wherein the arthritis is rheumatoid arthritis, knee osteoarthritis, tenosynonitis, periomarthritis, tendinitis, or coxitis.

5. The method of claim 1 , wherein the lactic acid bacterium is at least one bacterium belonging to a genus selected from the group consisting of the genera Lactobacillus, Bifidobacterium, Enterococcus, Leuconostoc, Streptococcus, Lactococcus, Pediococcus , and Weissella.

6. The method of claim 5 , wherein the bacterium belonging to the genus Lactobacillus is at least one bacterium selected from the group consisting of Lactobacillus amylovorus, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus zeae, Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus gallinarum, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus delbrueckii subsp. bulgaricus, and Lactobacillus johnsonii.

7. The method of claim 1 , further comprising adding at least one known substance having an anti-inflammatory effect to the composition.

8. The method of claim 7 , wherein the known substance having an anti-inflammatory effect is collagen, glucosamine, chondroitin, fatty acid, amino acid, or a salt thereof, or a combination thereof.

9. The method of claim 8 , wherein the combination is with glucosamine or a salt thereof and chondroitin or a salt thereof.

10. A method for decreasing IL-6 expression in a subject in need thereof comprising:
(a) disrupting cells of a lactic acid bacterium to produce a composition comprising disrupted cells of the lactic acid bacterium;
(b) administering an effective amount of the composition to the subject, wherein the average long diameter and/or surface area of each disrupted cell is 90% or less of that of the lactic acid bacterial cells before disruption.

11. The method of claim 10 , wherein the lactic acid bacterium is Lactobacillus acidophilus CL-92 strain (FERM BP-4981), Lactobacillus amylovorus CP1563 strain (FERM BP-11255) or Lactobacillus gasseri CP2305 strain (FERM BP-11331), or a mutant strain thereof or derived strain therefrom.

12. The method of claim 10 , wherein the lactic acid bacterium is at least one bacterium belonging to a genus selected from the group consisting of the genera Lactobacillus, Bifidobacterium, Enterococcus, Leuconostoc, Streptococcus, Lactococcus, Pediococcus , and Weissella.

13. The method of claim 12 , wherein the bacterium belonging to the genus Lactobacillus is at least one bacterium selected from the group consisting of Lactobacillus amylovorus, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus zeae, Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus gallinarum, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus delbrueckii subsp. bulgaricus , and Lactobacillus johnsonii.

Assignees

• Itoh Kikuji
• Fujiwara Shigeru
• Asahi Group Holdings Ltd

Inventors

• Itoh Kikuji
• Fujiwara Shigeru

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A23L33/135

  Bacteria or derivatives thereof, e.g. probiotics · CPC title

• A61K31/20

  having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids · CPC title